FDA Approval in Urothelial Cancer, Plus Mechanisms of Acquired Resistance in KRAS G12C–Mutant Cancers

On this episode, we're reviewing the FDA full approval of a therapy for previously treated patients with advanced urothelial cancer. Then, we'll hear about a trial that investigated potential mechanisms of acquired resistance to KRAS G12C inhibitors in patients with KRAS G12C–mutant cancers.

---